Refine by
Disease Severity Articles & Analysis
217 news found
Due to the large outbreaks of ZIKA virus-associated disease, the World Health Organization declared ZIKA virus a public health emergency of international concern in early 2016, greatly accelerating the pace of global research into ZIKA virus. Several disease models of Zika virus infection have been established in mice and non-human primates ...
Gene therapy for glaucoma is a promising field of research focused on developing treatments to address the underlying causes of the disease, potentially offering more effective and long-lasting solutions than current options. ...
Influenza A virus strains of all subtypes have been isolated from wild birds, but disease is rare. Some isolated influenza A viruses cause severe disease in poultry and, in rare cases, in humans. ...
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in ...
ByeTheRNA
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. ...
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
The following people are not suitable for HIFU ultrasound: If you are over 70 years old and have severe skin laxity, I think HIFU ultrasound is no longer suitable for you! They are more in need of remodelling of the skeletal support structure. Pregnant women, patients with severe heart disease and diabetes, such people should be guided by their ...
Both FFRsten and EFR indices showed a very significant positive correlation with coronary CT angiography-derived FFR, making this non-invasive, comparative test a promising tool for supporting the prevention and functional evaluation of coronary disease. VCAST has several advantages over the invasive procedure used to obtain FFR, including being non-invasive, ...
“Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes,” said Dr. ...
ByBayer AG
” AIR works to simplify the process of matching patients to clinical trials by helping gastroenterologists better understand disease severity more quickly and consistently. The technology uses computational algorithms integrated with existing colonoscopy imagery and videos to determine clinical trial eligibility, speeding up the clinical trial timelines ...
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD ...
ByBayer AG
(“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. ...
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by ...
The human genome has approximately 180,000 exomes, which are approximately 30 Mb in length, and the majority of disease-causing mutations among monogenic genetic diseases have been reported to be concentrated in the exome region. ...
This vaccine induced immunity has waned over time and with low booster uptake and no natural infections, the population is more susceptible to severe disease. China’s current booster uptake in over 80's is 40%, whilst Hong Kong’s primary series uptake was 34% back in February 2022 when it saw a large spike in cases due to the BA.1 omicron variant. ...